Clinical Biomarkers Market Report 2026

Clinical Biomarkers Market Overview

• Clinical Biomarkers market size has reached to $33.75 billion in 2025 • Expected to grow to $59.44 billion in 2030 at a compound annual growth rate (CAGR) of 12.1% • Growth Driver: Rising Aging Population Is Anticipated To Fuel Clinical Biomarker Market • Market Trend: Industry Leaders Transform Biomarker Testing With Innovative Blood Solutions • North America was the largest region in 2025.

What Is Covered Under Clinical Biomarkers Market?

Clinical biomarkers refer to quantifiable biological traits identifying normal or diseased bodily functions, such as chemicals or physiological indices. Clinical biomarkers help enhance patient care and personalized medicine by offering valuable data about a person's health condition, disease progression, and prospective therapeutic targets. The main offerings in clinical biomarkers are products and services. A product is anything that is sold to satisfy a customer's need or desire, whether it is physical or intangible, clinical biomarker products are used to aid in disease and condition diagnosis. The various technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and others. The various clinical areas include cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease biomarkers, immunological biomarkers, non-invasive prenatal testing, and others. These are used in various applications such as clinical diagnostic and translational research and also by various end-users such as contract research organizations (cros), research and academic laboratories, biopharmaceutical and biotech companies, diagnostic centers, and others.

What Is The Clinical Biomarkers Market Growth Forecast?

The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $59.44 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for personalized therapies, rising investments in biomarker-driven drug development, expansion of translational research programs, growing use of real-world clinical data, increasing adoption of advanced sequencing technologies. Major trends in the forecast period include increasing adoption of precision medicine biomarkers, rising use of multi-omics biomarker platforms, growing integration of AI-based biomarker analytics, expansion of companion diagnostics development, enhanced focus on early disease detection.

Global Clinical Biomarkers Market Segmentation

1) By Offering: Product, Service 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), Other Technologies 3) By Clinical Area: Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Immunological Biomarker, Non-Invasive Prenatal Testing, Other Clinical Areas 4) By Application: Clinical Diagnostic, Translational Research 5) By End User: Contract Research Organizations (CROs), Research And Academic Laboratories, Biopharmaceutical And Biotech Companies, Diagnostic Centers, Other End Users Subsegments: 1) By Product: Diagnostic Kits, Reagents, Assay Kits, Instruments 2) By Service: Biomarker Discovery Services, Analytical Services, Clinical Trial Services, Data Analysis Services

What Is The Driver Of The Clinical Biomarkers Market?

The rising aging population is expected to propel the growth of the clinical biomarker market going forward. An aging population refers to a demographic shift characterized by an increasing proportion of elderly individuals within a society over time. The aging global population is associated with an increased prevalence of age-related diseases, creating a need for biomarkers to improve early diagnosis and disease management. For instance, in February 2025, according to the World Health Organization, a UK-based intergovernmental organization, globally, the population of adults 60 and over is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the rising aging population is driving the clinical biomarker industry.

Key Players In The Global Clinical Biomarkers Market

Major companies operating in the clinical biomarkers market are Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.

Global Clinical Biomarkers Market Trends and Insights

Major companies operating in the clinical biomarkers market are focusing on developing innovative solutions such as biomarker blood tests. A biomarker blood test is a diagnostic method that assesses specific biomolecules present in the blood to provide information about various physiological or pathological conditions in the body. For instance, in July 2023, Quanterix Corporation, a US-based ultra-sensitive digital immunoassay platform developing company launched the ‘LucentAD’. It is a biomarker blood test designed to aid in assessing patients who exhibit cognitive symptoms consistent with the initial indications of Alzheimer's disease (AD). LucentAD employs the extensively researched Simoa p-Tau 181 assay, which has undergone thorough examination in both large longitudinal and cross-sectional cohorts.

What Are Latest Mergers And Acquisitions In The Clinical Biomarkers Market?

In July 2024, Thermo Fisher Scientific Inc., a US-based global life sciences and laboratory equipment company, completed the acquisition of Olink Holding AB for an undisclosed amount. With this acquisition, Thermo Fisher aims to strengthen its position in the rapidly growing proteomics market, enhance its precision research and diagnostics capabilities, and expand its portfolio of high-throughput protein analysis solutions. Olink Holding AB is a Sweden-based biotechnology company specializing in advanced proteomics technologies that enable high-resolution protein measurement for research and clinical applications.

Regional Outlook

North America was the largest region in the clinical biomakers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Clinical Biomarkers Market?

The clinical biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development, biomarker testing, and biomarker data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical biomarkers market also includes sales of immunoassay kits, point-of-care testing devices, and genetic testing panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Clinical Biomarkers Market Report 2026?

The clinical biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the clinical biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.